As opposed to targeting the VEGF-A signaling pathway, perhaps VEGFR3 kinase blockers or neutralizing antibodies against VEGF-C may show therapeutic efficacy against specific subsets of angiosarcomas. The gene discussed is VEGFC; the disease is angiosarcoma.